Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2012

01-12-2012 | PRECLINICAL STUDIES

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression

Authors: Zarina J. D’Costa, Cheng-Mee Leong, Justin Shields, Charles Matthews, Merilyn H. Hibma

Published in: Investigational New Drugs | Issue 6/2012

Login to get access

Summary

Persistent infections with certain high-risk human papillomavirus (HPV) types such as 16 and 18 can result in the development of cervical cancer. Neither of the two prophylactic vaccines against HPV16 and 18 that are in current use have any therapeutic efficacy for prevalent HPV infections. Ablative therapy is widely used for the treatment of HPV cervical dysplasia however disease recurrence is a widely recognized problem. Thus there is a continuing need for therapeutic approaches for the treatment of HPV infections. The HPV16 E6 viral oncoprotein represses surface expression of the cellular adhesion molecule, E-cadherin. Reduced E-cadherin expression on HPV-infected keratinocytes is associated with lowered numbers of antigen-presenting Langerhans cells in the infected epidermis, potentially reducing immune surveillance for HPV. Four chemicals reported to up-regulate E-cadherin were screened for their ability to counteract E6 repression of surface E-cadherin. 5-Aza-2’-deoxycytidine (AzaDC), a DNA methyltransferase inhibitor, and Indole-3-carbinol (I3C), reported to increase E-cadherin through a p21Waf1/Cip1-dependent mechanism, had low cytotoxicity and increased or restored E-cadherin expression and adhesive function in HPV16 E6 expressing HCT116 cells. Doxorubicin, also known to induce p21Waf1/Cip1, increased E-cadherin in E6 expressing cells but had some associated cytotoxicity. Tamoxifen, which can restore adhesive function of surface E-cadherin, was ineffective in counteracting E6 repression of E-cadherin. AzaDC and I3C both show potential to restore antigen-presenting cells to HPV infected skin by antagonizing E6 repression of E-cadherin, thereby counteracting an important immune evasion mechanism of HPV16 and reinstating immune function at the infected site.
Literature
1.
2.
Saslow D, Wheeler CM (2007) Human papillomavirus vaccines: who will pay, who will receive, when to administer? Ethn Dis 17(2 Suppl 2):S2-8-13PubMed
3.
4.
5.
Ault KA (2007) Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 107(2 Suppl 1):S31–33PubMedCrossRef
6.
7.
Soutter WP (1997) A comparison of cryocauterisation, laser vaporisation and large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology 17 (4):419; author reply 419. doi:10.​1080/​0144361975011307​8
8.
Greenfield I, Cuthill S (2001) Antivirals. Human papillomaviruses Clinical and scientific advances (eds JC Sterling and SK Tyring):120‚ Äì130
9.
Wierrani F, Kubin A, Jindra R, Henry M, Gharehbaghi K, Grin W, Soltz-Szotz J, Alth G, Grunberger W (1999) 5-aminolevulinic acid-mediated photodynamic therapy of intraepithelial neoplasia and human papillomavirus of the uterine cervix–a new experimental approach. Cancer Detect Prev 23(4):351–355PubMedCrossRef
10.
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196–200. doi:10.​1038/​ni758 PubMedCrossRef
11.
Slade HB (1998) Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. European journal of dermatology : EJD 8 (7 Suppl):13-16; discussion 20-12
12.
van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ (2008) Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 358(14):1465–1473. doi:10.​1056/​NEJMoa072685 PubMedCrossRef
13.
Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, Kitchener HC (2008) Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res 14(16):5292–5299. doi:10.​1158/​1078-0432.​CCR-07-4760 PubMedCrossRef
14.
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6(9):3406–3416PubMed
15.
Goldstone SE, Palefsky JM, Winnett MT, Neefe JR (2002) Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45(4):502–507PubMedCrossRef
16.
Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8(12):3676–3685PubMed
17.
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847. doi:10.​1056/​NEJMoa0810097 PubMedCrossRef
18.
Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14(1):178–187. doi:10.​1158/​1078-0432.​CCR-07-1880 PubMedCrossRef
19.
Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727–735PubMedCrossRef
20.
21.
Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Backstrom BT, Doorbar J, Hibma M (2003) Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 77(15):8378–8385PubMedCrossRef
22.
23.
Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41(5):1751–1756PubMed
24.
Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M (1999) Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 5(4):937–941PubMed
25.
Liu J, Lian Z, Han S, Waye MMY, Wang H, Wu MC, Wu K, Ding J, Arbuthnot P, Kew M (2005) Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 25(7):1008–1017CrossRef
26.
Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V (1994) Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 54(17):4607–4609PubMed
27.
28.
29.
Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF (2006) High-throughput real-time quantitative reverse transcription PCR. Current protocols in molecular biology/edited by Frederick M Ausubel [et al] Chapter 15:Unit 15 18. doi:10.​1002/​0471142727.​mb1508s73
30.
Mueller S, Cadenas E, Schonthal AH (2000) p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res 60(1):156–163PubMed
31.
32.
Roger L, Jullien L, Gire V, Roux P (2010) Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci 123(Pt 8):1295–1305. doi:10.​1242/​jcs.​061002 PubMedCrossRef
33.
Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7):894–907. doi:10.​1101/​gad.​1640608 PubMedCrossRef
34.
Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, Scherf U, Shankavaram UT, Ziegler MS, Stewart C, Kouros-Mehr H, Cui H, Dolginow D, Scudiero DA, Pommier YG, Munroe DJ, Feinberg AP, Weinstein JN (2007) Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 6(2):391–403. doi:10.​1158/​1535-7163.​MCT-06-0609 PubMedCrossRef
35.
Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92(16):7416–7419PubMedCrossRef
36.
Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN (2001) Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 61(1):192–196PubMed
37.
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55(22):5195–5199PubMed
38.
Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26(1):16–17. doi:10.​1038/​79120 PubMedCrossRef
39.
Chang HW, Chow V, Lam KY, Wei WI, Yuen A (2002) Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 94(2):386–392. doi:10.​1002/​cncr.​10211 PubMedCrossRef
40.
Chen CL, Liu SS, Ip SM, Wong LC, Ng TY, Ngan HY (2003) E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer 39(4):517–523PubMedCrossRef
41.
Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43(8):3493–3496PubMed
42.
43.
44.
45.
46.
Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL (1998) Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273(7):3838–3847PubMedCrossRef
47.
Brew CT, Aronchik I, Hsu JC, Sheen JH, Dickson RB, Bjeldanes LF, Firestone GL (2006) Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer 118(4):857–868. doi:10.​1002/​ijc.​21445 PubMedCrossRef
48.
Meng Q, Goldberg ID, Rosen EM, Fan S (2000) Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat 63(2):147–152PubMedCrossRef
49.
Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL, Auborn K (1999) Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 19(3A):1673–1680PubMed
50.
Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J, Lee AV (2003) Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 63(17):5203–5208PubMed
51.
Janakiram NB, Steele VE, Rao CV (2009) Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prevention Research 2(1):52–59. doi:10.​1158/​1940-6207.​CAPR-08-0140 PubMedCrossRef
52.
53.
Momparler RL, Ayoub J (2001) Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S111–115PubMedCrossRef
54.
Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA (1995) Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55(20):4531–4535PubMed
55.
Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL (2008) Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 8:128. doi:10.​1186/​1471-2407-8-128 PubMedCrossRef
56.
Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16(3):301–308PubMedCrossRef
57.
Braakhuis BJ, van Dongen GA, van Walsum M, Leyva A, Snow GB (1988) Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected]. Invest New Drugs 6(4):299–304PubMedCrossRef
58.
Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635–1640. doi:10.​1182/​blood-2003-03-0687 PubMedCrossRef
59.
Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522–528. doi:10.​1002/​cncr.​11543 PubMedCrossRef
60.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794–1803. doi:10.​1002/​cncr.​21792 PubMedCrossRef
61.
Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18(5):956–962PubMed
62.
Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF (1981) Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res 5(6):453–462PubMedCrossRef
63.
64.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6):1129–1136PubMedCrossRef
65.
Shah R, El-Deiry WS (2004) p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biol Ther 3(9):871–875PubMedCrossRef
66.
Yang SZ, Kohno N, Kondo K, Yokoyama A, Hamada H, Hiwada K, Miyake M (1999) Adriamycin activates E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Int J Oncol 15(6):1109–1115PubMed
67.
Nagafuchi A, Takeichi M (1989) Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1(1):37–44PubMed
68.
Ozawa M, Ringwald M, Kemler R (1990) Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Natl Acad Sci USA 87(11):4246–4250PubMedCrossRef
69.
Nagafuchi A, Ishihara S, Tsukita S (1994) The roles of catenins in the cadherin-mediated cell adhesion: functional analysis of E-cadherin-alpha catenin fusion molecules. J Cell Biol 127(1):235–245PubMedCrossRef
70.
Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL (1998) Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngology–head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck. Surgery 118(6):810–815
71.
Jin L, Qi M, Chen DZ, Anderson A, Yang GY, Arbeit JM, Auborn KJ (1999) Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res 59(16):3991–3997PubMed
72.
Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78(2):123–129. doi:10.​1006/​gyno.​2000.​5847 PubMedCrossRef
73.
Michnovicz JJ, Bradlow HL (1990) Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 82(11):947–949PubMedCrossRef
74.
Howie H, Katzenellenbogen R, Galloway D (2009) Papillomavirus E6 proteins. Virology 384(2):324–334PubMedCrossRef
75.
Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA (2008) E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82(21):10408PubMedCrossRef
76.
Caberg JH, Hubert PM, Begon DY, Herfs MF, Roncarati PJ, Boniver JJ, Delvenne PO (2008) Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 29(7):1441–1447. doi:10.​1093/​carcin/​bgn145 PubMedCrossRef
77.
Yang Z, Zhang H, Kumar R (2005) Regulation of E-cadherin. Breast Canc Online 8(03)
78.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173–185PubMedCrossRef
Metadata
Title
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression
Authors
Zarina J. D’Costa
Cheng-Mee Leong
Justin Shields
Charles Matthews
Merilyn H. Hibma
Publication date
01-12-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-012-9803-0

Other articles of this Issue 6/2012

Investigational New Drugs 6/2012 Go to the issue

PHASE II STUDIES

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

PHASE I STUDIES

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

PRECLINICAL STUDIES

Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias

PRECLINICAL STUDIES

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

PRECLINICAL STUDIES

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

PHASE II STUDIES

A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits